Ishizaki F, Nishikawa S
Third Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Eur Neurol. 1988;28(5):291-4. doi: 10.1159/000116287.
In 21 parkinsonian patients, we investigated the contents of blood serotonin (5HT) and benzylamine oxidase (BzAO) before and during L-dopa therapy. Then, we studied the patients prospectively, and evaluated the relationship between 5HT and BzAO and the clinical characteristics. The levels of blood 5HT and BzAO varied not only with the treatment, but also with the duration and clinical type of the disease. We postulated that in certain types of Parkinson's disease, the generalized defect of 5HT and enzyme metabolism might primarily exist, and might influence the efficacy of L-dopa therapy and the prognosis of the disease.
在21例帕金森病患者中,我们研究了左旋多巴治疗前及治疗期间血液中血清素(5HT)和苄胺氧化酶(BzAO)的含量。然后,我们对患者进行了前瞻性研究,并评估了5HT和BzAO与临床特征之间的关系。血液中5HT和BzAO的水平不仅随治疗而变化,还随疾病的持续时间和临床类型而变化。我们推测,在某些类型的帕金森病中,可能主要存在5HT和酶代谢的全身性缺陷,这可能会影响左旋多巴治疗的疗效和疾病的预后。